Strategic Advisors LLC grew its stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 137.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,198 shares of the company's stock after acquiring an additional 40,116 shares during the period. Strategic Advisors LLC's holdings in Cellebrite DI were worth $1,345,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Wealth Enhancement Advisory Services LLC acquired a new stake in Cellebrite DI during the first quarter worth approximately $269,000. Handelsbanken Fonder AB grew its position in shares of Cellebrite DI by 749.9% in the first quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock valued at $29,508,000 after purchasing an additional 1,340,000 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Cellebrite DI by 46.2% during the first quarter. SG Americas Securities LLC now owns 306,287 shares of the company's stock worth $5,951,000 after purchasing an additional 96,758 shares during the period. California State Teachers Retirement System lifted its holdings in Cellebrite DI by 19.3% during the 4th quarter. California State Teachers Retirement System now owns 71,385 shares of the company's stock worth $1,573,000 after purchasing an additional 11,555 shares during the last quarter. Finally, Mackenzie Financial Corp bought a new stake in Cellebrite DI in the 4th quarter valued at $776,000. Institutional investors and hedge funds own 45.88% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts have weighed in on the company. JPMorgan Chase & Co. lowered their price objective on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research report on Monday, May 12th. Needham & Company LLC restated a "buy" rating and issued a $24.00 price target on shares of Cellebrite DI in a research note on Friday, June 6th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $22.43.
Read Our Latest Analysis on CLBT
Cellebrite DI Stock Down 0.8%
Shares of CLBT traded down $0.13 during trading hours on Friday, hitting $15.47. 1,416,116 shares of the company were exchanged, compared to its average volume of 1,472,701. Cellebrite DI Ltd. has a fifty-two week low of $11.47 and a fifty-two week high of $26.30. The company has a market cap of $3.70 billion, a price-to-earnings ratio of -16.11, a P/E/G ratio of 3.15 and a beta of 1.32. The firm's fifty day moving average is $17.91 and its 200 day moving average is $19.83.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. The firm had revenue of $107.55 million for the quarter, compared to the consensus estimate of $109.36 million. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. The business's revenue for the quarter was up 20.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.08 earnings per share. Analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current year.
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
